Abstract:Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disease (GVHD)-prevention and treatment strategies. Most notably, the implementation of post-transplantation cyclophosphamide (PTCy) has dramatically increased the safety and availability of this life-saving therapy. Given reductions in nonrelapse mortality (NRM) with these advances, the HCT community has placed even greater emphasis on developing ways to reduce relapse - the leading cause of death after HCT. When using RIC HCT, protection from relapse relies predominantly on graft-versus-leukemia (GVL) reactions. Donor lymphocyte infusion (DLI), adoptive cellular therapy, checkpoint inhibition, and post-HCT maintenance strategies represent approaches under study that aim to augment or synergize with the GVL effects of HCT. Optimizing donor selection algorithms to leverage GVL represents another active area of research. Many of these strategies seek to harness the effects of T cells, which for decades were felt to be the primary mediators of GVL and the focus of investigation in relapse reduction. However, there is growing interest in capitalizing on the ability of natural killer (NK) cells to yield potent anti-tumor effects. A potential advantage of NK cell-based approaches over T cell-mediated is the potential to reduce NRM in addition to relapse. By decreasing infection, without increasing the risk of GVHD, NK cells may mitigate NRM, while still yielding relapse reduction through identification and clearance of cancer cells. Most T cell-focused relapse-prevention strategies must weigh the benefits of relapse reduction against the increased risk of NRM from GVHD. In contrast, NK cells have the potential to reduce both, potentially tipping the scales significantly in favor of survival. Here, we will review the role of NK cells in GVL, optimization of NK cell match or mismatch, and burgeoning areas of research in NK cell therapy such as adoptive transfer and chimeric antigen receptor (CAR) NK cells.

Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease

Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Immune Tolerance Induced by Cytokines in Allogeneic Hematopoietic Stem Cell Transplantation

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Immunomodulation and Pharmacological Strategies in the Treatment of Graft-Versus-host Disease

Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Prophylaxis and Treatment of Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Donor Γδt Cells Promote Graft-Versus-leukemia Effect and Ameliorate Acute Graft-Versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

The impact of regulatory T cells on the graft-versus-leukemia effect

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD

Haploidentical stem cell transplantation for the treatment of leukemia: current status.

Haploidentical Hematopoietic Transplantation Without T-cell Depletion: Current Status and Future Perspectives.

Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.

Cellular Mechanism for Granulocyte-Colony Stimulating Factor in the Prevention of Graft-Versus-host Disease in Combined Bone Marrow and Peripheral Blood Transplantation for Hematological Malignancies: the Composition in Collection

Progress on research of cytokines in graft-versus-host disease and graft-versus-leukemia

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

Current Status of Haploidentical Stem Cell Transplantation for Leukemia

[Clinical Study on the Relapsd Leukemia Patients with Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation].

Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?